Identification of the human cytochromes P450 responsible for in vitro formation of R- and S-norfluoxetine

Journal of Pharmacology and Experimental Therapeutics

Volumn 297, Issue 3, 2001, Pages 1044-1050

  Ring, Barbara J ^a   Eckstein, James A ^a   Gillespie, Jennifer S ^a   Binkley, Shelly N ^a   VandenBranden, Mark ^a   Wrighton, Steven A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; NORFLUOXETINE;

ARTICLE; CATALYSIS; CORRELATION FUNCTION; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; LIVER MICROSOME; LIVER MICROSOME METABOLISM; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RACEMIC MIXTURE; STEREOISOMERISM;

ANTIBODIES, MONOCLONAL; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CATALYSIS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; FLUOXETINE; HUMANS; KINETICS; METHYLATION; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; STEREOISOMERISM; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0035016503     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Alfaro CL, Lam YWF, Simpson J and Ereshefsky L (1999) CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. J Clin Psychopharmacol 19:155-163.
2. Bergstrom RF, Wolen RL, Peyton AL, Goodwin MR, Kasper SC, Barton R, Schwertschlag U and Lemberger L (1991) Pharmacokinetics of R-and S-fluoxetine enantiomers and the effect of P450IID6 activity on their disposition in man. Pharm Res 9:S206.
3. Copeland RA (1996) Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis. John Wiley & Sons, New York.
4. Ekins S, VandenBranden M, Ring BJ, Gillespie JS, Yang TJ, Gelboin HV and Wrighton SA (1998) Further characterization of the expression in liver and catalytic activity of CYP2B6. J Pharmacol Exp Ther 286:1253-1259.
5. Fjordside L, Jeppesen U, Eap CB, Powell K, Baumann P and Brosen K (1999) The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacogenetics 9:55-60.
6. Greenlee WF and Poland A (1978) An improved assay of 7-ethoxycoumarin O-deethylase activity: induction of hepatic enzyme activity in C57B:6J and DBA/2J mice by phenobarbital, 3-methylcholanthrene and 2, 3, 7, 8-tetrachbrodibenzo-p-dioxin. J Pharmacol Exp Ther 205:596-605.
7. Gelboin HV, Krausz KW, Gonzalez FJ and Yang TJ (1999) Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: a new avenue for drug discovery. Trends Pharmacol Sci 20:432-438.
8. Harris JW, Rahman A, Kim B-R, Guengerich FP and Collins JM (1994) Metabolism of Taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54:4026-4035.
9. Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP and Shimada T (1997) Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 7:103-113.
10. Margolis JM, O'Donnell JP, Mankowski DC, Ekins S and Obach RS (2000) (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos 28:1187-1191.
11. Ring BJ, Binkley SN, VandenBranden M and Wrighton SA (1996) In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol 41:181-186.
12. Segel IH (1975) Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady State Enzyme Systems, John Wiley & Sons, New York.
13. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
14. Stevens JC and Wrighton SA (1993) Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. J Pharmacol Exp Ther 266: 964-971.
15. van der Hoeven TA and Coon MJ (1974) Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. J Biol Chem 249:6302-6310.
16. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Wright CE, Harmatz JS and Shader RI (1997) Human cytochrome mediated N-demethylation of fluoxetine in vitro. Psychopharmacology 132:402-407.
17. Wong DT, Bymaster FP and Engleman EA (1995) Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci 57:411-441.
18. Wrighton SA and Ring BJ (1994) Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharm Res 11:921-924.
19. Wrighton SA, Stevens JC, Becker GW and VandenBranden M (1993a) Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 306:240-245.
20. Wrighton SA, VandenBranden M, Stevens JC, Shipley LA and Ring BR (1993b) In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab Rev 25:453-484.